
VALIRX PLC — Investor Relations & Filings
ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Change of Registered Office | 2026-03-31 | English | |
| ValiRx Commercial Update Q1 2026 | 2026-03-26 | English | |
| ValiRx and TwinEdge to present Digital Twin data | 2026-03-24 | English | |
| Director/PDMR Shareholding | 2026-03-04 | English | |
| ValiRx forms ValiRx Animal Health Ltd subsidiary | 2026-03-02 | English | |
| Exercise of Warrants | 2026-01-19 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 33109023 | Change of Registered Office | 2026-03-31 | English | ||
| 33045657 | ValiRx Commercial Update Q1 2026 | 2026-03-26 | English | ||
| 33018480 | ValiRx and TwinEdge to present Digital Twin data | 2026-03-24 | English | ||
| 32875259 | Director/PDMR Shareholding | 2026-03-04 | English | ||
| 32859834 | ValiRx forms ValiRx Animal Health Ltd subsidiary | 2026-03-02 | English | ||
| 13006423 | Exercise of Warrants | 2026-01-19 | English | ||
| 34556027 | Replacement: Evaluation and Transfer Agreement | 2026-01-09 | English | ||
| 34555998 | New Evaluation and Material Transfer Agreement | 2026-01-09 | English | ||
| 34555958 | Holding(s) in Company | 2026-01-08 | English | ||
|
2025
6 filings
| |||||
| 9347356 | Holding(s) in Company | 2025-12-05 | English | ||
| 8576672 | Holding(s) in Company | 2025-11-24 | English | ||
| 8558646 | Holding(s) in Company | 2025-11-24 | English | ||
| 8482575 | Result of GM & Issue of Equity | 2025-11-20 | English | ||
| 8295975 | Holding(s) in Company | 2025-11-13 | English | ||
| 8166114 | Holding(s) in Company | 2025-11-10 | English | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for VALIRX PLC, but not for this combination of statement and period. Try a different combination.
| Line item | ! |
|---|---|
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ectin Research AB
Pharmaceutical company developing novel oncology treatments…
|
ECTIN B | SE | Professional, scientific and te… |
|
EdgeLab S.p.A.
Designs and manufactures marine and underwater solutions, i…
|
ELB | IT | Professional, scientific and te… |
|
Editas Medicine, Inc.
A clinical-stage genome editing company developing CRISPR m…
|
EDIT | US | Professional, scientific and te… |
|
EGF Theramed Health Corp.
Developing psychedelic drugs for mental health, diagnostic …
|
TMED | CA | Professional, scientific and te… |
|
Eikon Therapeutics, Inc.
Integrates live-cell imaging and computing to discover ther…
|
EIKN | US | Professional, scientific and te… |
|
Eledon Pharmaceuticals, Inc.
Clinical-stage biotech developing therapies for organ and a…
|
ELDN | US | Professional, scientific and te… |
|
Elicera Therapeutics AB
Clinical-stage immuno-oncology company developing cell and …
|
ELIC | SE | Professional, scientific and te… |
|
Elicio Therapeutics, Inc.
Clinical-stage biotech developing lymph node-targeted immun…
|
ELTX | US | Professional, scientific and te… |
|
EMYRIA LIMITED
Clinical-stage biotech developing mental health and neurolo…
|
EMD | AU | Professional, scientific and te… |
|
Energenesis Biomedical CO.,LTD.
Develops small molecule drugs for cellular energy regulatio…
|
6657 | TW | Professional, scientific and te… |
VALIRX PLC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/7998/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=7998 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=7998 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=7998 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 7998}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for VALIRX PLC (id: 7998)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.